Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Akari Therapeutics (AKTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 37,105
  • Shares Outstanding, K 15,857
  • Annual Sales, $ 0 K
  • Annual Income, $ -16,470 K
  • 60-Month Beta -3.75
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 12.41

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate 0.00
  • Number of Estimates 1
  • High Estimate 0.00
  • Low Estimate 0.00
  • Prior Year -0.03
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.26 +1.77%
on 05/24/19
4.20 -45.24%
on 04/26/19
-1.70 (-42.50%)
since 04/24/19
3-Month
1.76 +30.77%
on 03/06/19
9.20 -75.00%
on 03/14/19
+0.50 (+27.78%)
since 02/22/19
52-Week
1.56 +47.44%
on 12/31/18
9.20 -75.00%
on 03/14/19
+0.49 (+27.07%)
since 05/24/18

Most Recent Stories

More News
Thinking about buying stock in Aurora Cannabis Inc., Akari Therapeutics, Atossa Genetics Inc., Boeing Co., or Reebonz Holding Ltd.?

InvestorsObserver issues critical PriceWatch Alerts for ACB, AKTX, ATOS, BA, and RBZ.

AKTX : 2.30 (-1.71%)
ACBFF : 8.6900 (-12.80%)
ATOS : 2.60 (-0.38%)
BA : 354.90 (+1.24%)
Akari Reports Fourth Quarter and Full Year 2018 Financial Results and Business Highlights

-- Pivotal clinical trial for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) expected to start Q4 2019

AKTX : 2.30 (-1.71%)
Akari Therapeutics Announces Positive Initial Phase II Clinical Data in Orphan Skin Disease Bullous Pemphigoid

Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems...

AKTX : 2.30 (-1.71%)
Recent Analysis Shows Extra Space Storage, OPKO Health, El Pollo Loco, Willis Towers Watson Public, Molina Healthcare, and Akari Therapeutics Market Influences -- Renewed Outlook, Key Drivers of Growth

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Extra Space Storage Inc (NYSE:EXR),...

WLTW : 177.73 (-0.06%)
AKTX : 2.30 (-1.71%)
MOH : 132.14 (+3.68%)
OPK : 1.96 (+2.08%)
LOCO : 10.82 (+0.65%)
EXR : 106.98 (+0.27%)
Akari Therapeutics to Provide Update on its Eye Disease Program During Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

-- Interim data expected from Akari's Phase I/II clinical trial in atopic keratoconjunctivitis (AKC), a surface of the eye inflammatory disease

AKTX : 2.30 (-1.71%)
Thinking about buying stock in Akari Therapeutics, Presbia Plc, Roku Inc., Snap Inc., or Pareteum Corp.?

InvestorsObserver issues critical PriceWatch Alerts for AKTX, LENS, ROKU, SNAP, and TEUM.

AKTX : 2.30 (-1.71%)
ROKU : 95.78 (+6.45%)
SNAP : 11.56 (+3.96%)
LENS : 0.32 (-3.03%)
TEUM : 4.72 (+6.55%)
Advancing Clinical Trials for Leukemia Patients is Helping Improve Survival Rate

According to the Leukemia & Lymphoma Society, the world's largest voluntary health agency dedicated to blood cancer, In 2018, 60,300 people are expected to be diagnosed with leukemia and that there are...

AKTX : 2.30 (-1.71%)
CELG : 95.24 (-0.41%)
LLY : 116.79 (-0.02%)
GERN : 1.55 (+1.97%)
CELGZ : 0.66 (+6.45%)
MBRX : 1.11 (-0.89%)
Positive FDA Meeting Outlines Path Ahead for Akari Therapeutics's Coversin in Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA)

Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems...

AKTX : 2.30 (-1.71%)
Factors of Influence in 2019, Key Indicators and Opportunity within EnLink Midstream, Pepsico, Arista Networks, Maiden, GCI Liberty, and Akari Therapeutics -- New Research Emphasizes Economic Growth

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of EnLink Midstream, LLC (NYSE:ENLC),...

ENLC : 10.91 (+0.09%)
AKTX : 2.30 (-1.71%)
ANET : 255.94 (+0.61%)
MHLD : 0.63 (+5.91%)
PEP : 129.50 (-0.36%)
GLIBA : 59.97 (+0.15%)
Alexion's (ALXN) Earnings Beat Estimates in Q4, Shares Up

Alexion (ALXN) exceeds earnings and sales estimates in the fourth quarter of 2018 on strong performance by Soliris.

AKTX : 2.30 (-1.71%)
ACHN : 2.84 (+1.07%)
HALO : 15.41 (+0.13%)
ALXN : 127.15 (+1.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators mostly agree with the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade AKTX with:

Business Summary

Akari Therapeutics PLC is a biopharmaceutical company. It focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. The Company's lead drug consist of Coversin is a recombinant small protein, which acts on complement component-C5,...

See More

Key Turning Points

2nd Resistance Point 2.56
1st Resistance Point 2.43
Last Price 2.30
1st Support Level 2.21
2nd Support Level 2.13

See More

52-Week High 9.20
Fibonacci 61.8% 6.28
Fibonacci 50% 5.38
Fibonacci 38.2% 4.48
Last Price 2.30
52-Week Low 1.56

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar